AVNS Earnings

AVNS reported its earnings on 2026-02-24, showcasing a revenue of 180.90M against an estimate of 176.13M, resulting in a 2.71% surprise. The EPS was 0.29, surpassing the expected 0.24 by 20.83%. The stock experienced a -10.44% price change on the earnings day and a -7.42% change over the next five days, reflecting market reactions to the results.

Following AVNS's earnings announcement on 2026-02-24, the stock price moved by -10.44% on the day of the release. Over the subsequent five days, it saw a -7.42% change. Historically, AVNS's stock price tends to shift by an average of 3.45% in the 10 days leading up to earnings and 2.21% in the 10 days following, providing insight into potential market.

For 2026/Q1, analysts estimate AVNS's annual revenue to reach 169.50M, while the EPS is projected at 0.23. These estimates reflect recent revisions, with revenue estimates unchanged by 0% and EPS estimates unchanged by 0% over the past three months, indicating analyst expectation in the company's performance.

The correlation between AVNS's stock price and earnings forecast revisions shows that positive revisions in revenue or EPS often strengthen the stock's fundamentals. Over the past three months, revenue estimates for FY2025 were unchanged by 0%, while EPS estimates moved unchanged by 0%. This trend suggests that price dips could present buying opportunities for investors.

Based on historical trends, AVNS's stock price typically moves by 3.45% in the 10 days before its earnings and 2.21% in the 10 days after. For the upcoming 2026/Q1 earnings, analysts expect an EPS of 0.23 and revenue of 169.50M.

The company reported strong financial performance with record high revenue and raised guidance for both revenue and EPS. Despite the divestiture impact, the acquisition of Nexus Medical is accretive, and strategic transitions are underway to mitigate tariff impacts. The Q&A indicates confidence in continued growth and operating leverage, although some management responses lacked clarity. Overall, the sentiment leans positive due to robust financial metrics and optimistic guidance.